The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells
复制标题
DOI:
10.3892/ijo.2017.4219
复制
发表时间:
2018-02-01
影响因子:
5.2
通讯作者:
Ogawa, Kazuhiko
中科院分区:
文献类型:
--
作者:
Taketo, Kosuke;Konno, Masamitsu;Ogawa, Kazuhiko
N-6-methyladenosine (m(6)A) is the most abundant epitranscriptome modification in mammalian mRNA. Recent years have seen substantial progress in m(6)A epitranscriptomics, indicating its crucial roles in the initiation and progression of cancer through regulation of RNA stabilities, mRNA splicing, microRNA processing and mRNA translation. However, by what means m(6)A is dynamically regulated or written by enzymatic components represented by methyltransferase-like 3 (METTL3) and how m(6)A is significant for each of the numerous genes remain unclear. We focused on METTL3 in pancreatic cancer, the prognosis of which is not satisfactory despite the development of multidisciplinary therapies. We established METTL3-knockdown pancreatic cancer cell line using short hairpin RNA. Although morphologic and proliferative changes were unaffected, METTL3-depleted cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5-fluorouracil, cisplatin and irradiation. Our data suggest that METTL3 is a potent target for enhancing therapeutic efficacy in patients with pancreatic cancer. In addition, we performed cDNA expression analysis followed by gene ontology and protein-protein interaction analysis using the Database for Annotation, Visualization, and Integrated Discovery and Search Tool for the Retrieval of Interacting Genes/Proteins databases, respectively. The results demonstrate that METTL3